HSBC WAR. CALL 06/24 TDXP/ DE000HG7X979 /
07/06/2024 21:35:14 | Chg.0.0000 | Bid21:59:58 | Ask21:59:58 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.0390EUR | 0.00% | 0.0160 Bid Size: 10,000 |
0.0460 Ask Size: 10,000 |
TECDAX | 3,600.00 - | 19/06/2024 | Call |
GlobeNewswire
23/01
Bluebeam Harnesses the Power of AI and Customer Passion to Drive Innovation in the Built World
GlobeNewswire
11/12/2023
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune c...
GlobeNewswire
07/11/2023
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
GlobeNewswire
12/06/2018
Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire
13/12/2016
MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire
06/12/2016
MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire
06/12/2016
MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire
28/11/2016
MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire
17/11/2016
MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire
15/11/2016
MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire
08/11/2016
Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire
03/11/2016
MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire
02/11/2016
MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire
20/10/2016
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody